Skip to content

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Amgen logo
AmgenAMGN
$3.34+4.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$1.02+10.5%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$0.60-445%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$0.41+10.9%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$0.24-167%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s EPS (diluted)?
IDEAYA Biosciences, Inc. (IDYA) reported EPS (diluted) of -$1.11 in Q1 2026.
How has IDEAYA Biosciences, Inc.'s EPS (diluted) changed year-over-year?
IDEAYA Biosciences, Inc.'s EPS (diluted) decreased by 35.4% year-over-year, from -$0.82 to -$1.11.
What is the long-term trend for IDEAYA Biosciences, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s EPS (diluted) has grown at a -1.8% compound annual growth rate (CAGR), from -$1.41 to -$1.31.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.